glp 1 liver enzymes Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) for the management of nonalcoholic fatty disease (NAFLD): A systematic review - Lv - 2020 - Endocrinology, Diabetes & Metabolism Mechanism of action for GLP-1R

Summary of phase 2 clinical trials of GLP1R agonists for PD Ex-4: exenatide-4, mTOR: mechanistic target of rapamycin, IRS1: insulin receptor substrate 1, MDS-UPDRS: Movement Disorder Society-Sponsored Revision of the Unified Parkinsons Disease Rating Scale, PD: Parkinsons disease, PKB: protein kinase B, DAergic: dopaminergic, GLP1R: glucagon-like peptide-1 receptor.

Regardless of participants type 2 diabetes status, researchers found that people receiving tirzepatide injections lost about 7% more weight than those receiving semaglutide injections in the first year on the medication

In a study of 376 patients, 328 (87.2%) received setmelanotide for a mean follow-up of 52 weeks

I think, because they had such a minor reaction and slow weight loss that they dropped out